Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer

Zhen Ye, Mai Mohamed Abdelmoaty, Vishakha V. Ambardekar, Stephen M. Curran, Shetty Ravi Dyavar, Lora L. Arnold, Samuel M. Cohen, Devendra Kumar, Yazen Alnouti, Don W. Coulter, Rakesh K. Singh, Joseph A. Vetro

Research output: Contribution to journalArticlepeer-review

Abstract

RNA interference molecules have tremendous potential for cancer therapy but are limited by insufficient potency after i.v. administration. We previously found that Chol-DsiRNA polyplexes formed between cholesterol-modified dicer-substrate siRNA (Chol-DsiRNA) and the cationic diblock copolymer PLL[30]-PEG[5K] greatly increase the activity of Chol-DsiRNA against a stably expressed reporter mRNA in primary murine syngeneic breast tumors after daily i.v. dosing. Here, we provide a more thorough preliminary preclinical study of Chol-DsiRNA polyplexes against the therapeutically relevant target protein, STAT3. We found that Chol-DsiSTAT3 polyplexes greatly increase plasma exposure, distribution, potency, and therapeutic activity of Chol-DsiSTAT3 in primary murine syngeneic 4T1 breast tumors after i.v. administration. Furthermore, inactive Chol-DsiCTRL polyplexes are well tolerated by healthy female BALB/c mice after chronic i.v. administration at 50 mg Chol-DsiCTRL/kg over 28 days. Thus, Chol-DsiRNA polyplexes may be a good candidate for Phase I clinical trials to improve the treatment of breast cancer and other solid tumors.

Original languageEnglish (US)
Article number102363
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume33
DOIs
StatePublished - Apr 2021

Keywords

  • Chol-DsiRNA polymer micelles
  • Chol-siRNA polymer micelles
  • Drug delivery
  • DsiRNA
  • RNA interference

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer'. Together they form a unique fingerprint.

Cite this